Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R, Perez A, Patel R, Zehngebot L, Allen H, Bosserman L, DiCarlo B, Kennedy A, Giuliano A, Calfa C, Molthrop D, Mani A, Chen HW, Dering J, Adams B, Kotler E, Press MF, Brugge JS, Curtis C, Slamon DJ.
Hurvitz SA, et al. Among authors: zoeller jj.
Nat Commun. 2020 Nov 17;11(1):5824. doi: 10.1038/s41467-020-19494-2.
Nat Commun. 2020.
PMID: 33203854
Free PMC article.
Clinical Trial.